Neurology® Podcast

American Academy of Neurology
undefined
Dec 2, 2013 • 40min

December 3 2013 Issue

1) Practice variability in brain death determination and 2) Topic of the month: Maintenance of Certification. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Dr. Jeff Frank about his paper on practice variability in brain death determination. Dr. Roy Strowd is reading our e-Pearl of the week about prion protein problems. In the next part of the podcast Dr. Elliot Dimberg interviews Dr. Janice Massey on part one of the orientation of new processes to the Maintenance of Certification. The participants had nothing to disclose except Drs. Burns, Strowd and Massey.Dr. Burns serves as Podcast Editor for Neurology; and has received research support for consulting activities with CSL Behring and Alexion Pharmaceuticals.Dr. Strowd serves on the editorial team for the Neurology Resident and Fellow Section. Dr. Massey serves on the AAN Board of Directors; the editorial board of Seminars in Neurology; and received unrestricted educational grants from Allergan, Inc. and Merz harmaceuticals, LLC for Annual Duke Advanced EMG and Chemodenervation Workshop.
undefined
Dec 1, 2013 • 21min

Delayed Recall - December 2013 - Biostatistics II

More topics in biostatistics
undefined
Nov 25, 2013 • 22min

November 26 2013 Issue

1) Temporal trends in new exposure to antiepileptic drug monotherapy and suicide-related behavior and 2) Topic of the month: Area of functional symptoms and conversion disorder. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Matt Wong interviews Dr. Mary Jo Pugh about her paper on temporal trends in new exposure to antiepileptic drug monotherapy and suicide-related behavior. Dr. Roy Strowd is reading our e-Pearl of the week about Garcin syndrome. In the next part of the podcast Dr. Shanna Patterson interviews Dr. Jon Stone about treatment of functional neurologic symptoms. The participants had nothing to disclose except Drs. Pugh, Strowd and Stone.Dr. Pugh serves as an associate editor of BMC Health Services Research and BMC Geriatrics; serves on the scientific advisory board of the Journal of Managed Care Pharmacy; receives research support from the Veterans Administration health services research and development service.Dr. Strowd serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Stone receives speaker honoraria from the Movement Disorders Society, Norwegian Neuropsychiatric Association, British Medical Association, Royal College of Psychiatrists, UCB, Tribunals Judiciary (UK) and St Louis Dept of Neurology; does expert witness work and runs a free patient information website.
undefined
Nov 18, 2013 • 23min

November 19 2013 Issue

1) Fibroblast growth factor-21 being a sensitive biomarker of mitochondrial disease and 2) Topic of the month: Area of functional symptoms and conversion disorder. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. James Addington interviews Dr. Carolyn Sue about her paper on fibroblast growth factor-21 being a sensitive biomarker of mitochondrial disease. Dr. Roy Strowd is reading our e-Pearl of the week about MAD for seizures. In the next part of the podcast Dr. Shanna Patterson interviews Dr. Jon Stone about functional neurologic symptoms and how to discuss this diagnosis with patients. The participants had nothing to disclose except Drs. Sue, Strowd and Stone.Dr. Sue receives research support from the National Health and Medical Research Council of Australia.Dr. Strowd serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Stone receives speaker honoraria from the Movement Disorders Society, Norwegian Neuropsychiatric Association, British Medical Association, Royal College of Psychiatrists, UCB, Tribunals Judiciary (UK) and St Louis Dept of Neurology; does expert witness work and runs a free patient information website.
undefined
Nov 11, 2013 • 25min

November 12 2013 Issue

1) Sensitivity of MRI spine compared to CT myelography in orthostatic headache with CSF leak and 2) Topic of the month: Area of functional symptoms and conversion disorder. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Heather Harle interviews Dr. Amaal Starling about her paper on sensitivity of MRI spine compared to CT myelography in orthostatic headache with CSF leak. Dr. Roy Strowd is reading our e-Pearl of the week about Rosenthal fibers. In the next part of the podcast Dr. Shanna Patterson interviews Dr. Jon Stone about functional symptoms and conversion disorder within the domain of psychiatry. The participants had nothing to disclose except Drs. Strowd and Stone.Dr. Strowd serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Stone receives speaker honoraria from the Movement Disorders Society, Norwegian Neuropsychiatric Association, British Medical Association, Royal College of Psychiatrists, UCB, Tribunals Judiciary (UK) and St Louis Dept of Neurology; does expert witness work and runs a free patient information website.
undefined
Nov 4, 2013 • 27min

November 5 2013 Issue

1) Primary leptomeningeal lymphoma and 2) Topic of the month: Area of functional symptoms and conversion disorder. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Dr. David Schiff about his paper on primary leptomeningeal lymphoma. Dr. Roy Strowd is reading our e-Pearl of the week about anti-NMDA receptor encephalitis. In the next part of the podcast Dr. Shanna Patterson interviews Dr. Jon Stone about definitions and etiology of functional symptoms and conversion disorder. The participants had nothing to disclose except Drs. Burns, Schiff, Strowd and Stone.Dr. Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with CSL Behring and Alexion Pharmaceuticals.Dr. Schiff serves as an editorial board member of Neurology® and Neurosurgery; received travel related expenses without personal compensation from Merck Sereno; serves on the scientific advisory board for Genetech, Inc.; is a consultant without personal compensation for Tau Therapeutics; serves on the data and safety monitoring boards for Celldex Therapeutics, Inc. and Vascular Biogenics Ltd. and receives royalties from UptoDate.Dr. Strowd serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Stone receives speaker honoraria from the Movement Disorders Society, Norwegian Neuropsychiatric Association, British Medical Association, Royal College of Psychiatrists, UCB, Tribunals Judiciary (UK) and St Louis Dept of Neurology; does expert witness work and runs a free patient information website.
undefined
Nov 1, 2013 • 53min

Delayed Recall - November 2013 - Pediatric Neurology Topics

Autoimmune disorders, stroke, epilepsy, and movement disorders
undefined
Oct 28, 2013 • 22min

October 29 2013 Issue

1) Pretreatment cognitive deficits and treatment effects in childhood epilepsy and 2) Topic of the month: Multiple sclerosis therapy and treatment. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Nick Brenton interviews Dr. Tracy Glauser about his paper on pretreatment cognitive deficits and treatment effects in childhood epilepsy. Lara Marcuse talks about being diagnosed with cancer after listening to Ted Burns discuss his diagnosis in our September 3 podcast. Dr. Adam Numis is reading our e-Pearl of the week about ophthalmologic findings in neurocysticercosis. In the next part of the podcast Dr. Mark Keegan interviews Dr. Douglas Goodin about interferons and copaxone in multiple sclerosis. The participants had nothing to disclose except Drs. Glauser, Numis, Keegan, and Goodin.Dr. Glauser serves on the scientific advisory board for AssureRx Health, Inc.; serves on the speakers' bureau and receives honoraria from Supernus Pharmaceuticals; receives royalties from the publication of the book Pediatric Epilepsy; receives royalty payments for optimization of drug selection software algorithms, AssureRx Health, Inc.; holds stock options in AssureRx Health, Inc.; has patents for optimization of drug selection software algorithms, neurocognitive computing algorithms and suicide prediction algorithms; is a consultant for Supernus Pharmaceuticals, Sunovion Pharmaceuticals, Inc., Eisai, Inc., UCB, Lundbeck Inc., Questcor Pharmaceuticals, Inc, Upsher-Smith, AssureRx Health, Inc.; receives license fees from AssureRx Health, Inc. for optimization of drug selection software algorithms and receives research support from the NIH.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Keegan serves as Chief Editor of eMedicine and receives research support from Terumo BCT.Dr. Goodin receives research support from Novartis; had travel costs reimbursed for occasional community lectures, symposia and/or academic talks sponsored by Bayer Schering Pharma, Teva Pharmaceutical Industries Ltd., Merck Serono. Genzyme and Novartis.
undefined
Oct 21, 2013 • 17min

October 22 2013 Issue

1) Dementia management quality measures and 2) Topic of the month: Multiple sclerosis therapy and treatment. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Jeff Burns interviews Dr. Amy Sanders about her paper on dementia management quality measures. Dr. Adam Numis is reading our e-Pearl of the week about Leber's hereditary optic neuropathy. In the next part of the podcast Dr. Mark Keegan interviews Dr. Alasdair Coles about alemtuzumab treatment of multiple sclerosis. The participants had nothing to disclose except Drs. Burns, Sanders, Numis, Keegan, and Coles.Dr. Jeff Burns serves on the editorial board for Journal of Alzheimer's Disease; receives royalties for the publications of Early diagnosis and treatment of mild cognitive impairment and Dementia: An atlas of investigation and diagnosis; is a consultant for PRA International and receives research support from the NIH, Alzheimer's Drug Discovery Foundation, Elan, Janssen Pharmaceuticals Inc., Wyeth, Pfizer Inc, Novartis Pharmaceuticals Ltd, Danone, Avid Radiopharmaceuticals, Merck Serono and for clinical trials.Dr. Sanders is a member of a federal advisory committee (MEDCAC); received honoraria for serving on peer-review panels from the CMMI and PCORI; and research support from the Einstein CTSA Grant from the National Center for Research Resources, a component of the NIH and NIH roadmap for Medical Research; loan repayment support from LRP/NIA. Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Keegan serves as Chief Editor of eMedicine and receives research support from Terumo BCT.Dr. Coles is a co-editor of Advances in Clinical Neuroscience and Rehabilitation; serves on the scientific advisory board for the Multiple Sclerosis Society of GB & NI, International Society for Neuroimmunology, Genzyme Corporation steering committee, UK Advisory Board, Merck Serono; is a consultant and receives speakers' honoraria from Nil, Merck Serono, Genzyme Corporation, Bayer Schering Pharma; and has a patent for IL-21 as a marker of autoimmunity after alemtuzumab treatment.
undefined
Oct 14, 2013 • 25min

October 15 2013 Issue

1) Vagus nerve stimulation for the treatment of epilepsy and 2) Topic of the month: Multiple sclerosis therapy and treatment. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Antel Patel interviews Dr. George Morris about his paper on vagus nerve stimulation for the treatment of epilepsy. Dr. Adam Numis is reading our e-Pearl of the week about vitamin B6 and epilepsy. In the next part of the podcast Dr. Mark Keegan interviews Dr. Robert Fox about dimethylfumarate for multiple sclerosis. The participants had nothing to disclose except Drs. Patel, Morris, Numis, Keegan, and Fox.Dr. Patel serves as Book editor for the Journal of Child Neurology; receives research support from UCB and Eisai Inc.Dr. Morris performs clinical care involving vagus nerve stimulation (5% effort) in his practice; serves on the speakers' bureaus of UCB, Cyberonics, Lundbeck, Inc.; is a consultant for UCB, Cyberonics, Lundbeck, Inc.; receives honoraria from UCB, Cyberonics, Lundbeck. Inc; receives research support from UCB, Cyberonics, Lundbeck. Inc.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Keegan serves as Chief Editor of eMedicine and receives research support from Terumo BCT.Dr. Fox serves as an editorial board member of Neurology and Multiple Sclerosis Journal; serves on the scientific advisory board for Biogen Idec, Novartis; is a consultant for Allozyne, Avanir, Biogen Idec, Novartis, Questcor, EMD Serono, and Teva Pharmaceutical Industries Ltd.; receives research support from Novartis, National MS Society and NIH.

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app